Literature DB >> 30287171

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Tim F Greten1, Chunwei Walter Lai2, Guangfu Li3, Kevin F Staveley-O'Carroll4.   

Abstract

Treatment options for patients with hepatocellular carcinoma are rapidly changing based on positive results from phase 3 trials of targeted and immune-based therapies. More agents designed to target specific pathways and immune checkpoints are in clinical development. Some agents have already been shown to improve outcomes of patients with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the Food and Drug Administration or have been recently approved. We summarize the targeted and immune-based agents in trials of patients with advanced hepatocellular carcinoma and discuss the future of these strategies for liver cancer.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Checkpoint Inhibitor; Human; Tumor

Mesh：

Substances：

Year:  2018        PMID： 30287171      PMCID： PMC6340758          DOI： 10.1053/j.gastro.2018.09.051

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


  111 in total

1.  Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Authors:  Lorenza Rimassa; Eric Assenat; Markus Peck-Radosavljevic; Marc Pracht; Vittorina Zagonel; Philippe Mathurin; Elena Rota Caremoli; Camillo Porta; Bruno Daniele; Luigi Bolondi; Vincenzo Mazzaferro; William Harris; Nevena Damjanov; Davide Pastorelli; María Reig; Jennifer Knox; Francesca Negri; Jörg Trojan; Carlos López López; Nicola Personeni; Thomas Decaens; Marie Dupuy; Wolfgang Sieghart; Giovanni Abbadessa; Brian Schwartz; Maria Lamar; Terri Goldberg; Dale Shuster; Armando Santoro; Jordi Bruix
Journal:  Lancet Oncol       Date:  2018-04-03       Impact factor: 41.316

2.  Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Authors:  G K Abou-Alfa; S Qin; B-Y Ryoo; S-N Lu; C-J Yen; Y-H Feng; H Y Lim; F Izzo; M Colombo; D Sarker; L Bolondi; G Vaccaro; W P Harris; Z Chen; R A Hubner; T Meyer; W Sun; J J Harding; E M Hollywood; J Ma; P J Wan; M Ly; J Bomalaski; A Johnston; C-C Lin; Y Chao; L-T Chen
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

Review 3.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

Review 4.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

5.  Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

Authors:  Zeyan Pan; Shengmeng Di; Bizhi Shi; Hua Jiang; Zhimin Shi; Ying Liu; Yi Wang; Hong Luo; Min Yu; Xiuqi Wu; Zonghai Li
Journal:  Cancer Immunol Immunother       Date:  2018-08-04       Impact factor: 6.968

6.  Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.

Authors:  Longhao Sun; Hao Guo; Ruoyu Jiang; Li Lu; Tong Liu; Xianghui He
Journal:  Tumour Biol       Date:  2015-08-07

7.  Expression of the c-met protooncogene in human hepatocellular carcinoma.

Authors:  K Suzuki; N Hayashi; Y Yamada; H Yoshihara; Y Miyamoto; Y Ito; T Ito; K Katayama; Y Sasaki; A Ito
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

8.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 10.  Contextual determinants of TGFβ action in development, immunity and cancer.

Authors:  Charles J David; Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2018-07       Impact factor: 94.444
View more
  65 in total

1.  Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.

Authors:  Kesang Li; Suying Qian; Mengmeng Huang; Mengjie Chen; Ling Peng; Jianwen Liu; Wen Xu; Jianfen Xu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.

Authors:  Huijuan Cheng; Guodong Sun; Hao Chen; Yu Li; Zhijian Han; Yangbing Li; Peng Zhang; Luxi Yang; Yumin Li
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

3.  Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma.

Authors:  Botao Pan; Wenxiu Pan; Zheng Lu; Chenglai Xia
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-16       Impact factor: 2.629

4.  LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1.

Authors:  Kai Chen; Yifu Hou; Rui Liao; Youzan Li; Hongji Yang; Jun Gong
Journal:  Oncogene       Date:  2021-04-06       Impact factor: 9.867

5.  Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.

Authors:  Xiao Liang; Yudi Wang; Hui Shi; Mengmeng Dong; Haobo Han; Quanshun Li
Journal:  Int J Nanomedicine       Date:  2021-03-30

Review 6.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

7.  Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.

Authors:  Wei Li; Hong Wu; Xuewen Xu; Yange Zhang
Journal:  Aging (Albany NY)       Date:  2021-04-18       Impact factor: 5.682

Review 8.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.

Authors:  Xiang-Yuan Luo; Kong-Ming Wu; Xing-Xing He
Journal:  J Exp Clin Cancer Res       Date:  2021-05-18

Review 9.  Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Joji Tani; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.

Authors:  De-Chen Yu; Xiang-Yi Chen; Xin Li; Hai-Yu Zhou; De-Quan Yu; Xiao-Lei Yu; Yi-Cun Hu; Rui-Hao Zhang; Xiao-Bo Zhang; Kun Zhang; Jiang-Dong An
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.